Krisztina N Ware, OTD | |
7430 Spring Village Dr, Springfield, VA 22150-4446 | |
(703) 923-4684 | |
(703) 923-4681 |
Full Name | Krisztina N Ware |
---|---|
Gender | Female |
Speciality | Occupational Therapy |
Experience | 14 Years |
Location | 7430 Spring Village Dr, Springfield, Virginia |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669819173 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0119003520 (Virginia) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Neuro-vision Therapy Center Llc | 9436559812 | 2 |
News Archive
NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis").
For decades, scientists have been trying to develop a vaccine that prevents mosquitoes from spreading malaria among humans.
Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 3 days ago
Provider Name | Neuro-vision Therapy Center Llc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1205401882 PECOS PAC ID: 9436559812 Enrollment ID: O20210608000394 |
News Archive
NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis").
For decades, scientists have been trying to develop a vaccine that prevents mosquitoes from spreading malaria among humans.
Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Krisztina N Ware, OTD 7430 Spring Village Dr, Springfield, VA 22150-4446 Ph: (703) 923-4684 | Krisztina N Ware, OTD 7430 Spring Village Dr, Springfield, VA 22150-4446 Ph: (703) 923-4684 |
News Archive
NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis").
For decades, scientists have been trying to develop a vaccine that prevents mosquitoes from spreading malaria among humans.
Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 3 days ago
Tyler Schorr, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5501 Backlick Rd, Suite 118, Springfield, VA 22151 Phone: 703-750-1204 Fax: 703-750-1206 | |
Allison Nayer, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: The Chesapeake Center, Inc., 6506 Loisdale Rd., Suite 300, Springfield, VA 22150 Phone: 703-924-4100 | |
Rebecca A Wise, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6506 Loisdale Rd, Suite 302, Springfield, VA 22150 Phone: 703-924-4100 | |
Dots4pedsllc-developmental Outpatient Therapy Services For Pediatrics Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8208 Smithfield Ave, Springfield, VA 22152 Phone: 703-451-0452 | |
Sasha Gang, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6506 Loisdale Rd, Third Floor, Springfield, VA 22150 Phone: 703-922-5048 | |
Kate Allen, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7001a Loisdale Rd, Springfield, VA 22150 Phone: 703-971-0602 Fax: 703-971-0606 | |
Katelyn Noble, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6541 Franconia Rd, Springfield, VA 22150 Phone: 703-922-6800 |